Aug 12 2010
OptiMedica has signed an agreement with Topcon, a Japanese provider of optometric and ophthalmic products, to sell its glaucoma and retina assets. OptiMedica has made the divesture to focus on the developing technologies for cataract treatments. The sale will provide additional funding to the company for its laser cataract surgery system launch.
OptiMedica revolutionized the retinal photocoagulation field by launching the PASCAL (PAttern SCAn Laser) method in 2006. The PASCAL Method is a partially automated pattern generation technique that enables swift laser pulse delivery in a sequence. It offers various advantages over traditional photocoagulators, including better clinical results, less pain for patients, and enhanced efficiency. The offerings from PASCAL include the Patterned Laser Trabeculoplasty application, the PASCAL Streamline, the PASCAL SlimLine, and the original PASCAL Photocoagulator.
OptiMedica will now focus on the laser cataract surgery. The company delivers laser energy with user interface design, high-speed scanning, and sophisticated control systems, applying its expertise. The company has also developed a femtosecond laser system to improve the cataract procedure significantly. The laser system will offer cataract surgeons the same mixture of efficiency, safety, performance, control, and precision that was provided by PASCAL technologies.
The CEO of OptiMedica, Mark J. Forchette stated that Topcon is an exceptional distribution partner for PASCAL photocoagulator. He added that the company will focus on delivering the innovations in the laser cataract surgical technology, as the glaucoma and retina portfolio has been handed over to Topcon.
Source: http://www.optimedica.com/